U.S. Stock Market Midday Update
Compass Therapeutics fell 9.51%. Based on recent key news:
<ol>
<li>
On April 27, Compass Therapeutics' cancer treatment failed to meet the secondary endpoint for overall survival in a trial, leading to a drop in stock price. Although progression-free survival showed improvement, the data was difficult to interpret due to a high crossover rate in the control group, causing the stock to drop 23% in pre-market trading. Source: WSJ
</li>
<li>
On April 29, Canaccord Genuity lowered the target price for Compass Therapeutics from $13 to $7, reflecting market concerns about the company's prospects. Source: MarketWatch
</li>
<li>
On April 27, analyst Charles Zhu maintained a buy rating on Compass Therapeutics with a target price of $6, despite a strong buy consensus in the market for the stock. Source: LifeSci Capital The biopharmaceutical industry faces regulatory uncertainties.
</li>
</ol>
Stocks with High Trading Volume in the Industry
KalVista Pharmaceuticals rose 38.75%. Based on recent key news:
<ol>
<li>
On April 29, Italy's Chiesi Group announced the acquisition of KalVista Pharmaceuticals for $1.9 billion, with an acquisition price of $27 per share, a 36% premium over the average stock price in the past month. This news drove KalVista's stock price up significantly by 38.6%. Source: Reuters
</li>
<li>
On April 29, Chiesi Group stated that this acquisition would strengthen its strategy in the rare disease field and expand its commercial footprint in the U.S. This move reflects Chiesi's long-term expansion vision in the rare immunology sector. Source: Reuters
</li>
<li>
On April 30, KalVista Pharmaceuticals' stock price significantly increased following Chiesi Group's acquisition proposal, with the market reacting positively to the news, further driving the stock price up. Source: Reuters The rare disease sector is active in mergers and acquisitions, attracting high market attention.
</li>
</ol>
AbbVie rose 3.50%, with active trading. Based on recent key news:
<ol>
<li>
On April 29, AbbVie announced its first-quarter financial report, with adjusted earnings per share of $2.65, exceeding market expectations of $2.59, and revenue reaching $15 billion, a 12% year-over-year increase. This performance exceeded expectations, driving the stock price up. Source: Barron's
</li>
<li>
On April 29, AbbVie raised its full-year adjusted earnings per share forecast for 2026 to $14.08 to $14.28, an increase from the previous forecast of $13.96 to $14.16. This move boosted market confidence, further driving the stock price up. Source: RTTNews
On April 29, AbbVie’s immunology drugs Skyrizi and Rinvoq saw sales growth of 31% and 23%, respectively, exceeding market expectations and becoming the main drivers of performance growth. Source: AASTOCKS Strong demand for immunology drugs drives performance growth.
</li>
</ol>
Regeneron Pharmaceuticals fell 7.24%. Based on recent key news:
<ol>
<li>
On April 29, Regeneron Pharmaceuticals announced its first-quarter financial report, with adjusted earnings per share of $9.47, exceeding expectations, but net income declined year-on-year, leading to a drop in stock price. The company's net income was $727 million, down from $808 million in the same period last year, affecting market confidence.
</li>
<li>
On April 29, Regeneron Pharmaceuticals announced a drug pricing agreement with the U.S. government to lower the prices of certain drugs. Although this move aims to enhance market competitiveness, concerns about profitability in the short term have intensified, putting pressure on the stock price.
</li>
<li>
On April 30, the company projected a GAAP gross margin of 77% to 78% for 2026, lower than previous expectations. The increase in adjusted R&amp;D expenses and selling and administrative expenses further affected investor sentiment, leading to a decline in stock price. The pharmaceutical industry faces pricing pressure, with significant capital outflows.
</li>
</ol>
Stocks ranked at the top of the industry by market capitalization
Amgen fell 0.46%, with increased trading volume. Based on recent key news:
<ol>
<li>
On April 28, the U.S. FDA proposed to withdraw the approval of Amgen's drug Tavneos due to its failure to demonstrate efficacy and safety issues, including liver damage and death cases. This news put pressure on Amgen's stock price.
</li>
<li>
On April 29, analyst ratings showed Amgen with a hold rating and not included in the recommended buy list, indicating market caution regarding its future performance.
</li>
<li>
On April 28, Amgen collaborated with the FDA for regulatory review of clinical trial data, showing the company's positive progress in drug development. The biopharmaceutical industry faces regulatory challenges
</li>
</ol>

CMPX

Compass Therapeutics fell 9.51%; KalVista Pharmaceuticals rose 38.75%, with a transaction volume of USD 1.509 billion; AbbVie rose 3.50%, with a transaction volume of USD 1.433 billion; Regeneron Pharmaceuticals fell 7.24%, with a transaction volume of USD 829 million; Amgen fell 0.46%, with a market value of USD 182.4 billion

Price Alert

Compass Therapeutics

U.S. stock market update: Compass Therapeutics down 9.51%, concerns in the market triggered by failed cancer trials and target price downgrade